| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
γ-Tocotrienol (25 μM; 24 h) efficiently suppresses P-gp protein and mdr1 mRNA expression levels. (25 μM and 50 μM; 24 h) also suppresses P-gp's efflux activity and mdr1 promoter activity. [2]. γ-Tocotrienol (at 25 μM and 50 μM; 24 hours) can decrease NF-κB transcriptional activity as well as the activation of the NF-κB signaling pathway [2]. γ-Tocotrienol (50 μM; 48 h) efficiently prevents the nuclear translocation of p65 caused by TNFα [2]. fluorescent imaging [2]
|
|---|---|
| ln Vivo |
In myelosuppressive and fatal TBI in mice, the liposomal formulation of gamma-tocotrienol, GT3-Nano (20 mol% gamma-tocotrienol) (10 mg/kg, 6 mol%; intravenous injection; single dose, studied for 100 days), is efficacious in lowering sublethal [3]. Mice treated with the internal radiation therapy agent 153Sm-EDTMP can benefit from a fast recovery of hematopoietic components when administered GT3-Nano (50 mg/kg by intravenous injection) [3].
|
| Cell Assay |
Immunofluorescence [2]
Cell Types: MCF-7/Adr Cell Tested Concentrations: 50 μM Incubation Duration: 48 hrs (hours) Experimental Results: The red fluorescence of p65 in the nucleus weakened, indicating that TNFα inhibits the nuclear translocation of p65. |
| Animal Protocol |
Animal/Disease Models: C57/BL6 black mouse (6-8 weeks old) total body irradiation [3]
Doses: 16, 24, 32, 50mg/kg Route of Administration: intravenous (iv) (iv)injection; injection administration; mice were treated for 100 days Observations: Demonstrated dose-dependent radioprotection, achieving 90% survival against lethal 9 Gy total body irradiation (TBI) at a dose of 50 mg/kg. MPP2 and CMP are upregulated in bone marrow progenitor cells in GT3-Nano-treated mice. |
| References |
|
| Additional Infomation |
Gamma-tocotrienol is a tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 7 and 8 and a farnesyl chain at position 2. A vitamin E family member that has potent anti-cancer properties against a wide-range of cancers. It has a role as an antioxidant, an antineoplastic agent, a plant metabolite, a radiation protective agent, an apoptosis inducer and a hepatoprotective agent. It is a tocotrienol and a vitamin E.
gamma-Tocotrienol has been reported in Amaranthus hybridus, Amaranthus cruentus, and other organisms with data available. |
| Molecular Formula |
C28H42O2
|
|---|---|
| Molecular Weight |
410.6319
|
| Exact Mass |
410.318
|
| CAS # |
14101-61-2
|
| PubChem CID |
5282349
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
530.8±49.0 °C at 760 mmHg
|
| Flash Point |
218.4±24.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
10.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
30
|
| Complexity |
625
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2=C(C([H])([H])[H])C(C([H])([H])[H])=C(C([H])=C2C([H])([H])C([H])([H])[C@@]1(C([H])([H])[H])C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])O[H]
|
| InChi Key |
OTXNTMVVOOBZCV-WAZJVIJMSA-N
|
| InChi Code |
InChI=1S/C28H42O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-17-28(7)18-16-25-19-26(29)23(5)24(6)27(25)30-28/h11,13,15,19,29H,8-10,12,14,16-18H2,1-7H3/b21-13+,22-15+/t28-/m1/s1
|
| Chemical Name |
(2R)-2,7,8-trimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~243.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.09 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4353 mL | 12.1764 mL | 24.3528 mL | |
| 5 mM | 0.4871 mL | 2.4353 mL | 4.8706 mL | |
| 10 mM | 0.2435 mL | 1.2176 mL | 2.4353 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
